Skip to main content

Advertisement

Table 2 Mean levels of hormone measurements by group and according to menopausal status.

From: Low salivary testosterone levels in patients with breast cancer

  Controls (sd) Cases (sd) p-value
T    
pre 34.3 (16.1) 31.4 (15.3) 0.234
post 31.0 (17.6) 25.1(12.6) 0.002
overall 32.2 (17.5) 27.2 (13.9) < 0.001
E1    
pre 3.8 (2.9) 5.0 (2.9) 0.037
post 3.6 (2.1) 4.8 (4.8) 0.047
overall 3.7 (2.4) 4.9 (4.2) 0.006
E2    
pre 2.1 (2.1) 2.4 (2.0) 0.295
post 1.2 (0.8) 1.7 (1.3) < 0.001
overall 1.65 (1.3) 2.0 (1.6) 0.005
E3    
pre 5.2 (7.3) 2.7 (1.5) 0.001
post 3.7 (2.6) 3.6 (3.8) 0.734
overall 4.3 (4.9) 3.3 (3.3) 0.011
DHEAS    
pre 7.3 (4.8) 6.8 (4.9) 0.434
post 5.7 (4.2) 4.5 (3.7) 0.007
overall 6.4 (4.5) 5.3 (4.3) 0.007
T/E1    
pre 28.26 (46.7) 8.23 (7.6) < 0.001
post 22.97 (79.5) 8.74 (12.9) 0.021
overall 24.75 (68.5) 8.57 (11.4) 0.014
T/E2    
pre 19.34 (11.6) 19.90 (23.43) 0.667
post 34.09 (25.5) 25.86 (52.3) 0.063
overall 27.45 (21.7) 23.86 (44.6) 0.212
  1. T/E1 and T/E2, average ratios of testosterone over estrone and estradiol, respectively. Sd, standard deviation. P-values were computed using students' t-test. Testosterone (T) pg/ml, Estrone (E1) pg/ml, Estradiol (E2) pg/ml, Estriol (E3) pg/ml, DHEAS ng/ml